Clinical and Serologic Response to the 23-valent Polysaccharide Pneumococcal Vaccine in Children and Teens with Recurrent Upper Respiratory Tract Infections and Selective Antibody Deficiency

Jaime Estrada, Maria Najera, Natalie Pounds, Gabriel Catano, Anthony J Infante

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We report the clinical and serological response of 72 children and adolescents after immunization with the 23-valent polysaccharide pneumococcal vaccine (PPV23). All had been diagnosed with recurrent upper respiratory tract infections and low antipneumococcal immunity. Forty-five (62%) of these patients had received PCV7, the 7-serotype pneumococcal conjugated vaccine (Prevnar7). After immunization with the polysaccharide vaccine, 69 (96%) patients, including 42 of the 45 who had previously been immunized with the conjugate vaccine, had a positive clinical response including 12 patients (17%) whose serological response to the polysaccharide vaccine was inadequate. Clinical and serological response to PPV23 was assessed at approximately 1, 3 and 6 months after immunization. Our study also confirmed that a small group of patients with recurrent upper respiratory tract infections are unable to develop a normal response to pneumococcal and other bacterial polysaccharides despite vaccination with the newer conjugated vaccines. This immunodeficiency has been named selective antibody deficiency with normal immunoglobulins or impaired polysaccharide responsiveness. These patients did well after administration of intravenous IgG.

Original languageEnglish (US)
Pages (from-to)205-208
Number of pages4
JournalPediatric Infectious Disease Journal
Volume35
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Pneumococcal Vaccines
Respiratory Tract Infections
Antibodies
Polysaccharides
Immunization
Vaccines
Bacterial Polysaccharides
Conjugate Vaccines
Intravenous Administration
Immunoglobulins
Immunity
Vaccination
Immunoglobulin G

Keywords

  • 23-valent pneumococcal vaccine
  • children
  • recurrent upper respiratory tract infections
  • teens

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Clinical and Serologic Response to the 23-valent Polysaccharide Pneumococcal Vaccine in Children and Teens with Recurrent Upper Respiratory Tract Infections and Selective Antibody Deficiency. / Estrada, Jaime; Najera, Maria; Pounds, Natalie; Catano, Gabriel; Infante, Anthony J.

In: Pediatric Infectious Disease Journal, Vol. 35, No. 2, 01.02.2016, p. 205-208.

Research output: Contribution to journalArticle

@article{1d0a58b00e05472ab5dcc7a53dbc5b08,
title = "Clinical and Serologic Response to the 23-valent Polysaccharide Pneumococcal Vaccine in Children and Teens with Recurrent Upper Respiratory Tract Infections and Selective Antibody Deficiency",
abstract = "We report the clinical and serological response of 72 children and adolescents after immunization with the 23-valent polysaccharide pneumococcal vaccine (PPV23). All had been diagnosed with recurrent upper respiratory tract infections and low antipneumococcal immunity. Forty-five (62{\%}) of these patients had received PCV7, the 7-serotype pneumococcal conjugated vaccine (Prevnar7). After immunization with the polysaccharide vaccine, 69 (96{\%}) patients, including 42 of the 45 who had previously been immunized with the conjugate vaccine, had a positive clinical response including 12 patients (17{\%}) whose serological response to the polysaccharide vaccine was inadequate. Clinical and serological response to PPV23 was assessed at approximately 1, 3 and 6 months after immunization. Our study also confirmed that a small group of patients with recurrent upper respiratory tract infections are unable to develop a normal response to pneumococcal and other bacterial polysaccharides despite vaccination with the newer conjugated vaccines. This immunodeficiency has been named selective antibody deficiency with normal immunoglobulins or impaired polysaccharide responsiveness. These patients did well after administration of intravenous IgG.",
keywords = "23-valent pneumococcal vaccine, children, recurrent upper respiratory tract infections, teens",
author = "Jaime Estrada and Maria Najera and Natalie Pounds and Gabriel Catano and Infante, {Anthony J}",
year = "2016",
month = "2",
day = "1",
doi = "10.1097/INF.0000000000000964",
language = "English (US)",
volume = "35",
pages = "205--208",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical and Serologic Response to the 23-valent Polysaccharide Pneumococcal Vaccine in Children and Teens with Recurrent Upper Respiratory Tract Infections and Selective Antibody Deficiency

AU - Estrada, Jaime

AU - Najera, Maria

AU - Pounds, Natalie

AU - Catano, Gabriel

AU - Infante, Anthony J

PY - 2016/2/1

Y1 - 2016/2/1

N2 - We report the clinical and serological response of 72 children and adolescents after immunization with the 23-valent polysaccharide pneumococcal vaccine (PPV23). All had been diagnosed with recurrent upper respiratory tract infections and low antipneumococcal immunity. Forty-five (62%) of these patients had received PCV7, the 7-serotype pneumococcal conjugated vaccine (Prevnar7). After immunization with the polysaccharide vaccine, 69 (96%) patients, including 42 of the 45 who had previously been immunized with the conjugate vaccine, had a positive clinical response including 12 patients (17%) whose serological response to the polysaccharide vaccine was inadequate. Clinical and serological response to PPV23 was assessed at approximately 1, 3 and 6 months after immunization. Our study also confirmed that a small group of patients with recurrent upper respiratory tract infections are unable to develop a normal response to pneumococcal and other bacterial polysaccharides despite vaccination with the newer conjugated vaccines. This immunodeficiency has been named selective antibody deficiency with normal immunoglobulins or impaired polysaccharide responsiveness. These patients did well after administration of intravenous IgG.

AB - We report the clinical and serological response of 72 children and adolescents after immunization with the 23-valent polysaccharide pneumococcal vaccine (PPV23). All had been diagnosed with recurrent upper respiratory tract infections and low antipneumococcal immunity. Forty-five (62%) of these patients had received PCV7, the 7-serotype pneumococcal conjugated vaccine (Prevnar7). After immunization with the polysaccharide vaccine, 69 (96%) patients, including 42 of the 45 who had previously been immunized with the conjugate vaccine, had a positive clinical response including 12 patients (17%) whose serological response to the polysaccharide vaccine was inadequate. Clinical and serological response to PPV23 was assessed at approximately 1, 3 and 6 months after immunization. Our study also confirmed that a small group of patients with recurrent upper respiratory tract infections are unable to develop a normal response to pneumococcal and other bacterial polysaccharides despite vaccination with the newer conjugated vaccines. This immunodeficiency has been named selective antibody deficiency with normal immunoglobulins or impaired polysaccharide responsiveness. These patients did well after administration of intravenous IgG.

KW - 23-valent pneumococcal vaccine

KW - children

KW - recurrent upper respiratory tract infections

KW - teens

UR - http://www.scopus.com/inward/record.url?scp=84955415898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955415898&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000000964

DO - 10.1097/INF.0000000000000964

M3 - Article

C2 - 26517331

AN - SCOPUS:84955415898

VL - 35

SP - 205

EP - 208

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 2

ER -